Mads

KBRA Assigns AAA Rating to Oregon State Lottery Revenue Bonds, 2024 Series A - D; Affirms Rating for Parity Bonds

Retrieved on: 
Monday, April 1, 2024
Professional Services, Finance, Nature, AAA, Parity, Outlook, State, KBRA, Mads

KBRA assigns a long-term rating of AAA to the State of Oregon Department of Administrative Services: Oregon State Lottery Revenue Bonds, 2024 Series A (Tax-Exempt Projects & Refunding); Oregon State Lottery Revenue Bonds, 2024 Series B (Federally Taxable Projects); Oregon State Lottery Revenue Bonds, 2024 Series C (Tax-Exempt Refunding); and, Oregon State Lottery Revenue Bonds, 2024 Series D (Tax-Exempt Refunding).

Key Points: 
  • KBRA assigns a long-term rating of AAA to the State of Oregon Department of Administrative Services: Oregon State Lottery Revenue Bonds, 2024 Series A (Tax-Exempt Projects & Refunding); Oregon State Lottery Revenue Bonds, 2024 Series B (Federally Taxable Projects); Oregon State Lottery Revenue Bonds, 2024 Series C (Tax-Exempt Refunding); and, Oregon State Lottery Revenue Bonds, 2024 Series D (Tax-Exempt Refunding).
  • KBRA additionally affirms the long-term rating of AAA for parity Oregon State Lottery Revenue Bonds.
  • The rating actions reflect the following key credit considerations:
    The Lottery enjoys statewide support as an essential resource, funding 6.1% of FY 2023 State General Fund expenditures.
  • Sustained decline in Lottery sales that results in significantly diminished coverage of Lottery Revenue Bond debt service from unobligated net lottery proceeds.

Zerion Pharma A/S appoints Mads Aaboe Jensen as Vice President, Business Development

Retrieved on: 
Friday, September 1, 2023
CBL, Business development, Henley Business School, Roche, Innovation, RNA, Solubility, Doctor of Philosophy, Science, Molecular biology, Master of Science, Aarhus University, Mads, Management, Medicine

COPENHAGEN, Denmark, Sept. 1, 2023 /PRNewswire/ -- Zerion Pharma A/S ("ZERION") today announces that the Company has strengthened its management team with the appointment of Dr. Mads Aaboe Jensen as Vice President Business Development.

Key Points: 
  • COPENHAGEN, Denmark, Sept. 1, 2023 /PRNewswire/ -- Zerion Pharma A/S ("ZERION") today announces that the Company has strengthened its management team with the appointment of Dr. Mads Aaboe Jensen as Vice President Business Development.
  • Mads Aaboe will be responsible for the Company's business development and commercial activities relating to ZERION's Dispersome® technology that has proven to be very efficient in improving the solubility and bioavailability of small molecule drugs.
  • Mads Aaboe Jensen joins ZERION with more than 20 years of experience at the crossroads of science and business.
  • Furthermore, he has completed an executive CBL management & business education program at Henley Business School.

Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Key Component of the Company’s Cancer Immunotherapy Pipeline

Retrieved on: 
Tuesday, January 3, 2023
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Society for Immunotherapy of Cancer, Immunotherapy, Partnership, Patent, Society, Neoplasm, Patient, NYSE, Biopharmaceutical, Behavior, Paclitaxel, Macrophage, Tams, Therapy, B cell, Mads, US, Doxorubicin, Cell, Medical imaging, Cancer

The Notice of Allowance concludes the substantive examination of the patent application and is expected to result in the issuance of a U.S. patent after administrative processes are completed.

Key Points: 
  • The Notice of Allowance concludes the substantive examination of the patent application and is expected to result in the issuance of a U.S. patent after administrative processes are completed.
  • When issued, this patent will protect key elements of Navidea’s cancer immunotherapy product pipeline.
  • Navidea’s cancer immunotherapy product pipeline consists of a series of mannosylated-amine dextrans (“MADs”) that carry small molecule drug payloads that are attached to MADs by degradable linkers.
  • This important patent application covers key intellectual property critical to the continued development of our therapeutics pipeline.

New West Dental Lab Introduces EndSnorZ™ Sleep Appliance

Retrieved on: 
Monday, December 12, 2022
Mads, CDT, Sleep apnea, Muscle, Dentist, Bridge, Sleep, MAD, Vibration, Traction, Orientation, Ligament, Patient, The Closed Mouth, Mouth, Snoring, OSA, Tissue, Success, Dentistry, New West Records

LAKE HAVASU CITY, Ariz., Dec. 12, 2022 (GLOBE NEWSWIRE) -- New West Dental Lab, a full-service dental laboratory that has been serving dentists nationally for over 40 years, has announced a new addition to its family of mandibular advancement devices (MADs), the EndSnorZ™ Sleep Appliance.

Key Points: 
  • LAKE HAVASU CITY, Ariz., Dec. 12, 2022 (GLOBE NEWSWIRE) -- New West Dental Lab, a full-service dental laboratory that has been serving dentists nationally for over 40 years, has announced a new addition to its family of mandibular advancement devices (MADs), the EndSnorZ™ Sleep Appliance.
  • Dentists who trust New West with their crown & bridge restorations will find the EndSnorZ to be a reliable and precise 3D-printed appliance that fits well with the high-quality standards that the dental treatment of snoring and sleep apnea demands.
  • "I'm pleased to announce the availability of the EndSnorZ Sleep Appliance," said New West General Manager Hollie Taylor, CDT.
  • In its four decades of serving dentists across the country, New West Dental Lab has worked very closely with dental teams and vendor groups to provide an elevated patient experience.

EQS-News: invIOs GmbH: APEIRON Respiratory Therapies announces positive results from Phase I trial of inhaled APN01

Retrieved on: 
Monday, November 7, 2022
Medical University of Vienna, Blood pressure, Severe acute respiratory syndrome coronavirus 2, Heart, Ageing, MAD, SADS, Death, Degenerative disease, Vascular remodelling in the embryo, Kidney disease, Science, Principal, Safety, Adult, APN01, Department, Toxicity, Ventilation, COVID-19, Gene expression, ACE, Acute respiratory distress syndrome, Medical school, CEO, Inhalation, Lung, Pharmacology, PAH, Hypertensive emergency, Patient safety, ACE2, RAAS, Hydrolysis, Inflammation, Liver, Mads, Respiratory disease, Achievement, Kidney, Immunotherapy, Patient, Gesellschaft mit beschränkter Haftung, Pharmacokinetics, Administration, Vaccine, Pharmaceutical industry, Arester Earl

In a completed double-blind, placebo-controlled Phase 2 trial, intravenously administered APN01 showed potential clinical benefit against COVID-19.

Key Points: 
  • In a completed double-blind, placebo-controlled Phase 2 trial, intravenously administered APN01 showed potential clinical benefit against COVID-19.
  • With the current trial of inhaled APN01 and our previous Phase 2 trial using intravenous administration in COVID-19, we have shown that APN01 is a safe and well tolerated potential treatment approach for a number of respiratory diseases.
  • More information on the demerger of AResT and invIOs from APEIRON Biologics AG can be found on the invIOs website here .
  • The first EPiC-based candidate, APN401, is currently being evaluated in a clinical Phase 1b trial in patients with advanced solid tumors.

APEIRON Respiratory Therapies announces positive results from Phase I trial of inhaled APN01

Retrieved on: 
Thursday, November 3, 2022
Medical University of Vienna, Blood pressure, Severe acute respiratory syndrome coronavirus 2, Heart, Ageing, MAD, SADS, Death, Degenerative disease, Vascular remodelling in the embryo, GLOBE, Kidney disease, Science, Principal, Safety, Adult, APN01, Department, Toxicity, Ventilation, COVID-19, Gene expression, ACE, Acute respiratory distress syndrome, Medical school, CEO, Inhalation, Lung, Pharmacology, PAH, Hypertensive emergency, Patient safety, ACE2, RAAS, Hydrolysis, Inflammation, Liver, Mads, Respiratory disease, Achievement, Kidney, Immunotherapy, Patient, Gesellschaft mit beschränkter Haftung, Pharmacokinetics, Administration, Vaccine, Pharmaceutical industry, Arester Earl

In a completed double-blind, placebo-controlled Phase 2 trial, intravenously administered APN01 showed potential clinical benefit against COVID-19.

Key Points: 
  • In a completed double-blind, placebo-controlled Phase 2 trial, intravenously administered APN01 showed potential clinical benefit against COVID-19.
  • With the current trial of inhaled APN01 and our previous Phase 2 trial using intravenous administration in COVID-19, we have shown that APN01 is a safe and well tolerated potential treatment approach for a number of respiratory diseases.
  • The double-blind, placebo-controlled, dose-escalation study was designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of inhaled APN01.
  • The first EPiC-based candidate, APN401, is currently being evaluated in a clinical Phase 1b trial in patients with advanced solid tumors.

Global Sleep Apnea Oral Appliances Market Report 2022: High Burden of Sleep Apnea to Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 15, 2022
Medical Supplies, Medical Devices, Health, Hospitals, Telemedicine, Virtual Medicine, Managed Care, Online, Adoption, Mandibular advancement splint, TRD, Texas Homecare, Prevalence, Mads, Hospital, Population, Growth, USD, CPAP, Patient, OTC, Research, Sleep apnea, CAGR, Dentistry, Pharmaceutical industry

The "Sleep Apnea Oral Appliances Market by Product (Mandibular Advancement Devices & Tongue-Retaining Devices), Purchase Type (Physician-prescribed/Customized Oral Appliances & Online OTC Oral Appliances), End User (Homecare, Hospital) - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Sleep Apnea Oral Appliances Market by Product (Mandibular Advancement Devices & Tongue-Retaining Devices), Purchase Type (Physician-prescribed/Customized Oral Appliances & Online OTC Oral Appliances), End User (Homecare, Hospital) - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The mandibular advancement device segment accounted for the highest growth rate in the sleep apnea oral appliances market, by product, during the forecast period
    Based on product, the sleep apnea oral appliances market is divided into two main categories - mandibular advancement devices (MADs) and tongue-retaining devices (TRDs).
  • Base on purchase type, the sleep apnea oral appliances market is segmented into - physician-prescribed/ customized oral appliances and online OTC oral appliances.
  • The physician-prescribed/customized oral appliances segment accounted for the largest share of the sleep apnea oral appliances market in 2021.

DGAP-News: APEIRON Biologics commences clinical COVID-19 trial with inhaled APN01

Retrieved on: 
Tuesday, October 12, 2021
Inflammation, Pharmacokinetics, Jazz Pharmaceuticals, Infection, National, Department, Liver, SARS, VUMC, COVID-19, Kidney disease, ACE2, Cell, Heart, Nebulizer, Mads, Vanderbilt University Medical Center, APN01, Safety, Cancer, Inhalation, Neuroblastoma, World Health Organization, Lung, Pharmacology, PAH, Medical school, Chronic obstructive pulmonary disease, Degenerative disease, COPD, Blood pressure, Severe acute respiratory syndrome coronavirus 2, CMSO, CEO, Kidney, SADS, Therapy, Cell membrane, RAAS, NIH, Patient, Disease, Clinical trial, Government, World, University College, Oxford, Medical University of Vienna, Biomarker, Pulmonary hypertension, Pharmaceutical industry, Vaccine, APN01 (alunacedase alfa), APEIRON Biologics AG, APN01 (ALUNACEDASE ALFA), APEIRON BIOLOGICS AG

Romana Gugenberger PhD, CMSO of APEIRON Biologics AG, explains: "The start of this company sponsored trial for APN01 is a vital next step in our development approach.

Key Points: 
  • Romana Gugenberger PhD, CMSO of APEIRON Biologics AG, explains: "The start of this company sponsored trial for APN01 is a vital next step in our development approach.
  • Peter Llewellyn-Davies, CEO of APEIRON Biologics AG, adds: "We desperately need an effective treatment for COVID-19 and an inhaled application is an important strategic milestone for APEIRON.
  • This is the third clinical trial dedicated to the multi-armed initiative of developing APN01 into vital therapy options in COVID-19.
  • APEIRON Biologics' projects and technologies are based on a strong patent portfolio and partnerships with leading pharmaceutical companies and academic institutions.